Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Xocova Taken by Estimated 32,270 Patients as of Feb. 19: Shionogi
February 28, 2023
- Enhertu Approved in China for HER2 Positive Breast Cancer
February 28, 2023
- COVID-19 Drugs Haul Big Sales in 2022, Veklury Crosses 100 Billion Yen Line
February 27, 2023
- Pfizer Japan Files PARP Inhibitor Talazoparib for Breast and Prostate Cancer
February 27, 2023
- Astellas Presents Update on PI/II Study of AT845 for Late-Onset Pompe Disease
February 27, 2023
- Pfizer Japan Begins Amoxapine Recall, Ceases Shipments over Carcinogen Risks
February 27, 2023
- Ono Bags Right to Cue Biopharma’s Tregs-Inducing Bispecific Protein
February 24, 2023
- Shionogi’s Xocova Cuts Risks of Long COVID by 45%: Exploratory Data
February 24, 2023
- Opdivo Approved for NSCLC Neoadjuvant Use in Taiwan
February 24, 2023
- Teijin, Axcelead to Launch Drug Discovery Joint Venture
February 22, 2023
- Kidswell Bio Revs Up Biosimilar Push, G-Lasta, Eylea Follow-Ons in Development
February 22, 2023
- Pfizer Files RSV Vaccine in Japan
February 21, 2023
- FDA Target Date for Hot Flash Med Extended by 3 Months: Astellas
February 21, 2023
- Japan Approves Taisho’s Visceral Fat-Reducing Med as Nonprescription Drug
February 20, 2023
- US Patent Office Restarts PGR for Seagen Patent: Daiichi Sankyo
February 20, 2023
- PharmaEssentia Lays Out Sales Organization in Japan for 1st Product Launch
February 20, 2023
- Susmed Bags Japan Approval for Insomnia App
February 20, 2023
- IQVIA Pledges Push to Biopharma Startups in Japan
February 20, 2023
- Global PIII Launched for Xocova in Hospitalized Patients: Shionogi
February 20, 2023
- Mitsubishi Chemical Ups Full-Year Outlook on Gilenya Royalty Win
February 20, 2023
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…